Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device
Targeted biopsy of lesions identified on magnetic resonance imaging may enhance the detection of clinically relevant prostate cancers. We evaluated prostate cancer detection rates in 171 consecutive men using magnetic resonance ultrasound fusion prostate biopsy. Subjects underwent targeted biopsy fo...
Gespeichert in:
| Veröffentlicht in: | The Journal of urology Jg. 189; H. 1; S. 86 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.01.2013
|
| Schlagworte: | |
| ISSN: | 1527-3792, 1527-3792 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Targeted biopsy of lesions identified on magnetic resonance imaging may enhance the detection of clinically relevant prostate cancers. We evaluated prostate cancer detection rates in 171 consecutive men using magnetic resonance ultrasound fusion prostate biopsy.
Subjects underwent targeted biopsy for active surveillance (106) or persistently increased prostate specific antigen but negative prior conventional biopsy (65). Before biopsy, each man underwent multiparametric magnetic resonance imaging at 3.0 Tesla. Lesions on magnetic resonance imaging were outlined in 3 dimensions and assigned increasing cancer suspicion levels (image grade 1 to 5) by a uroradiologist. A biopsy tracking system was used to fuse the stored magnetic resonance imaging with real-time ultrasound, generating a 3-dimensional prostate model on the fly. Working from the 3-dimensional model, transrectal biopsy of target lesions and 12 systematic biopsies were performed with the patient under local anesthesia in the clinic.
A total of 171 subjects (median age 65 years) underwent targeted biopsy. At biopsy, median prostate specific antigen was 4.9 ng/ml and prostate volume was 48 cc. A targeted biopsy was 3 times more likely to identify cancer than a systematic biopsy (21% vs 7%). Prostate cancer was found in 53% of men, 38% of whom had Gleason grade 7 or greater cancer. Of the men with Gleason 7 or greater cancer 38% had disease detected only on targeted biopsies. Targeted biopsy findings correlated with level of suspicion on magnetic resonance imaging. Of 16 men 15 (94%) with an image grade 5 target (highest suspicion) had prostate cancer, including 7 with Gleason 7 or greater cancer.
Prostate lesions identified on magnetic resonance imaging can be accurately targeted using magnetic resonance ultrasound fusion biopsy by a urologist in clinic. Biopsy findings correlate with level of suspicion on magnetic resonance imaging. |
|---|---|
| AbstractList | Targeted biopsy of lesions identified on magnetic resonance imaging may enhance the detection of clinically relevant prostate cancers. We evaluated prostate cancer detection rates in 171 consecutive men using magnetic resonance ultrasound fusion prostate biopsy.
Subjects underwent targeted biopsy for active surveillance (106) or persistently increased prostate specific antigen but negative prior conventional biopsy (65). Before biopsy, each man underwent multiparametric magnetic resonance imaging at 3.0 Tesla. Lesions on magnetic resonance imaging were outlined in 3 dimensions and assigned increasing cancer suspicion levels (image grade 1 to 5) by a uroradiologist. A biopsy tracking system was used to fuse the stored magnetic resonance imaging with real-time ultrasound, generating a 3-dimensional prostate model on the fly. Working from the 3-dimensional model, transrectal biopsy of target lesions and 12 systematic biopsies were performed with the patient under local anesthesia in the clinic.
A total of 171 subjects (median age 65 years) underwent targeted biopsy. At biopsy, median prostate specific antigen was 4.9 ng/ml and prostate volume was 48 cc. A targeted biopsy was 3 times more likely to identify cancer than a systematic biopsy (21% vs 7%). Prostate cancer was found in 53% of men, 38% of whom had Gleason grade 7 or greater cancer. Of the men with Gleason 7 or greater cancer 38% had disease detected only on targeted biopsies. Targeted biopsy findings correlated with level of suspicion on magnetic resonance imaging. Of 16 men 15 (94%) with an image grade 5 target (highest suspicion) had prostate cancer, including 7 with Gleason 7 or greater cancer.
Prostate lesions identified on magnetic resonance imaging can be accurately targeted using magnetic resonance ultrasound fusion biopsy by a urologist in clinic. Biopsy findings correlate with level of suspicion on magnetic resonance imaging. Targeted biopsy of lesions identified on magnetic resonance imaging may enhance the detection of clinically relevant prostate cancers. We evaluated prostate cancer detection rates in 171 consecutive men using magnetic resonance ultrasound fusion prostate biopsy.PURPOSETargeted biopsy of lesions identified on magnetic resonance imaging may enhance the detection of clinically relevant prostate cancers. We evaluated prostate cancer detection rates in 171 consecutive men using magnetic resonance ultrasound fusion prostate biopsy.Subjects underwent targeted biopsy for active surveillance (106) or persistently increased prostate specific antigen but negative prior conventional biopsy (65). Before biopsy, each man underwent multiparametric magnetic resonance imaging at 3.0 Tesla. Lesions on magnetic resonance imaging were outlined in 3 dimensions and assigned increasing cancer suspicion levels (image grade 1 to 5) by a uroradiologist. A biopsy tracking system was used to fuse the stored magnetic resonance imaging with real-time ultrasound, generating a 3-dimensional prostate model on the fly. Working from the 3-dimensional model, transrectal biopsy of target lesions and 12 systematic biopsies were performed with the patient under local anesthesia in the clinic.MATERIALS AND METHODSSubjects underwent targeted biopsy for active surveillance (106) or persistently increased prostate specific antigen but negative prior conventional biopsy (65). Before biopsy, each man underwent multiparametric magnetic resonance imaging at 3.0 Tesla. Lesions on magnetic resonance imaging were outlined in 3 dimensions and assigned increasing cancer suspicion levels (image grade 1 to 5) by a uroradiologist. A biopsy tracking system was used to fuse the stored magnetic resonance imaging with real-time ultrasound, generating a 3-dimensional prostate model on the fly. Working from the 3-dimensional model, transrectal biopsy of target lesions and 12 systematic biopsies were performed with the patient under local anesthesia in the clinic.A total of 171 subjects (median age 65 years) underwent targeted biopsy. At biopsy, median prostate specific antigen was 4.9 ng/ml and prostate volume was 48 cc. A targeted biopsy was 3 times more likely to identify cancer than a systematic biopsy (21% vs 7%). Prostate cancer was found in 53% of men, 38% of whom had Gleason grade 7 or greater cancer. Of the men with Gleason 7 or greater cancer 38% had disease detected only on targeted biopsies. Targeted biopsy findings correlated with level of suspicion on magnetic resonance imaging. Of 16 men 15 (94%) with an image grade 5 target (highest suspicion) had prostate cancer, including 7 with Gleason 7 or greater cancer.RESULTSA total of 171 subjects (median age 65 years) underwent targeted biopsy. At biopsy, median prostate specific antigen was 4.9 ng/ml and prostate volume was 48 cc. A targeted biopsy was 3 times more likely to identify cancer than a systematic biopsy (21% vs 7%). Prostate cancer was found in 53% of men, 38% of whom had Gleason grade 7 or greater cancer. Of the men with Gleason 7 or greater cancer 38% had disease detected only on targeted biopsies. Targeted biopsy findings correlated with level of suspicion on magnetic resonance imaging. Of 16 men 15 (94%) with an image grade 5 target (highest suspicion) had prostate cancer, including 7 with Gleason 7 or greater cancer.Prostate lesions identified on magnetic resonance imaging can be accurately targeted using magnetic resonance ultrasound fusion biopsy by a urologist in clinic. Biopsy findings correlate with level of suspicion on magnetic resonance imaging.CONCLUSIONSProstate lesions identified on magnetic resonance imaging can be accurately targeted using magnetic resonance ultrasound fusion biopsy by a urologist in clinic. Biopsy findings correlate with level of suspicion on magnetic resonance imaging. |
| Author | Sonn, Geoffrey A Natarajan, Shyam Lieu, Patricia Huang, Jiaoti Dorey, Frederick J Marks, Leonard S Margolis, Daniel J A MacAiran, Malu |
| Author_xml | – sequence: 1 givenname: Geoffrey A surname: Sonn fullname: Sonn, Geoffrey A organization: Department of Urology, University of California-Los Angeles, Los Angeles, California 90095, USA – sequence: 2 givenname: Shyam surname: Natarajan fullname: Natarajan, Shyam – sequence: 3 givenname: Daniel J A surname: Margolis fullname: Margolis, Daniel J A – sequence: 4 givenname: Malu surname: MacAiran fullname: MacAiran, Malu – sequence: 5 givenname: Patricia surname: Lieu fullname: Lieu, Patricia – sequence: 6 givenname: Jiaoti surname: Huang fullname: Huang, Jiaoti – sequence: 7 givenname: Frederick J surname: Dorey fullname: Dorey, Frederick J – sequence: 8 givenname: Leonard S surname: Marks fullname: Marks, Leonard S |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23158413$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LAzEQhoNU7If-AQ-So5ddk-xnjlL8goKXel6yyaSm7CZ1kwj996ZYwdMMM-_7MO8s0cw6CwjdUpJTQuuHfb6Pk8sZoSwnbU54dYEWtGJNVjSczf71c7T0fk8ILauGXaE5K2jVlrRYoLgV0w4CKNwbd_BHbCwOn4BVmslgnMVO48PkfBABsBRWwoSjN3aHxWmnjQTcC58Ao9hZCEbiCbyzJyWOQ5iEd9EqrJMp0RR8J8c1utRi8HBzriv08fy0Xb9mm_eXt_XjJpPpvJDxpqacaygUBd1rUVcSZF0q0rZaKKVqphrdA-FatW2lpap5CQWIsoSUTmm2Qve_3JTgK4IP3Wi8hGEQFlz0HWUFJxWnBUnSu7M09iOo7jCZUUzH7u9V7AeGI3Gc |
| CitedBy_id | crossref_primary_10_1007_s00261_020_02606_3 crossref_primary_10_1016_j_juro_2017_07_038 crossref_primary_10_1007_s00345_014_1332_3 crossref_primary_10_1038_s41391_018_0062_9 crossref_primary_10_1155_2014_684127 crossref_primary_10_1016_j_future_2021_09_030 crossref_primary_10_1136_bmjsit_2019_000025 crossref_primary_10_1007_s00345_013_1080_9 crossref_primary_10_1016_j_ultrasmedbio_2020_01_017 crossref_primary_10_1002_nbm_3002 crossref_primary_10_1016_j_eururo_2013_10_048 crossref_primary_10_1007_s11604_013_0195_7 crossref_primary_10_1016_j_juro_2015_12_102 crossref_primary_10_1007_s00706_017_1919_7 crossref_primary_10_1016_j_urology_2017_01_048 crossref_primary_10_1007_s11934_016_0589_z crossref_primary_10_1016_j_compbiomed_2023_107840 crossref_primary_10_1038_nrurol_2013_195 crossref_primary_10_1016_j_juro_2016_03_149 crossref_primary_10_1038_nrclinonc_2015_70 crossref_primary_10_1148_radiol_14140524 crossref_primary_10_1016_j_juro_2015_04_062 crossref_primary_10_1118_1_4905104 crossref_primary_10_48095_cccu2014034 crossref_primary_10_1109_TBME_2017_2778007 crossref_primary_10_1016_j_juro_2018_07_026 crossref_primary_10_3389_fonc_2015_00030 crossref_primary_10_1148_ryai_240485 crossref_primary_10_1002_cncr_28140 crossref_primary_10_1002_ima_23178 crossref_primary_10_1111_bju_12593 crossref_primary_10_1186_s12859_023_05235_x crossref_primary_10_1016_j_eururo_2022_01_008 crossref_primary_10_1111_bju_12871 crossref_primary_10_1016_j_brachy_2017_07_008 crossref_primary_10_1002_cncr_29874 crossref_primary_10_4137_BECB_S34255 crossref_primary_10_1586_14737140_2016_1131155 crossref_primary_10_1109_TBME_2023_3326799 crossref_primary_10_1007_s00345_018_2400_x crossref_primary_10_1016_j_euo_2019_03_005 crossref_primary_10_1016_j_juro_2014_10_106 crossref_primary_10_1016_j_juro_2014_07_098 crossref_primary_10_1016_j_urolonc_2016_04_008 crossref_primary_10_1016_j_urolonc_2021_04_021 crossref_primary_10_1007_s13244_016_0466_9 crossref_primary_10_1016_j_eururo_2013_03_025 crossref_primary_10_1038_s42003_022_03104_6 crossref_primary_10_1371_journal_pone_0157854 crossref_primary_10_2147_RRU_S300868 crossref_primary_10_1109_TMI_2014_2375207 crossref_primary_10_1007_s40336_016_0214_7 crossref_primary_10_1016_j_juro_2012_12_081 crossref_primary_10_1007_s00261_016_0746_3 crossref_primary_10_1016_j_urolonc_2013_04_002 crossref_primary_10_1016_j_euf_2016_07_003 crossref_primary_10_1038_nrclinonc_2014_44 crossref_primary_10_1007_s00345_018_2605_z crossref_primary_10_1016_j_juro_2018_03_004 crossref_primary_10_1007_s11934_016_0628_9 crossref_primary_10_1002_nano_202100041 crossref_primary_10_1016_j_euo_2018_09_006 crossref_primary_10_1016_j_urolonc_2015_01_023 crossref_primary_10_1016_j_compbiomed_2024_109140 crossref_primary_10_1016_j_juro_2013_04_043 crossref_primary_10_1016_j_urology_2021_06_023 crossref_primary_10_1007_s11307_018_1235_6 crossref_primary_10_1177_1756287219842485 crossref_primary_10_2147_CMAR_S265058 crossref_primary_10_1007_s00261_015_0353_8 crossref_primary_10_1016_j_juro_2016_08_109 crossref_primary_10_5812_numonthly_93596 crossref_primary_10_3322_caac_21278 crossref_primary_10_1007_s00261_018_1495_2 crossref_primary_10_1101_cshperspect_a030619 crossref_primary_10_1016_j_euf_2017_11_010 crossref_primary_10_1007_s10334_022_01006_6 crossref_primary_10_1111_bju_13460 crossref_primary_10_12954_PI_14062 crossref_primary_10_1016_j_urolonc_2013_08_006 crossref_primary_10_1007_s00261_013_0018_4 crossref_primary_10_1007_s40140_013_0038_1 crossref_primary_10_1097_MOU_0000000000000389 crossref_primary_10_1109_TMI_2022_3218147 crossref_primary_10_3389_fonc_2022_880336 crossref_primary_10_1007_s10439_018_02187_9 crossref_primary_10_1109_TMI_2017_2777870 crossref_primary_10_1016_j_crad_2013_10_018 crossref_primary_10_1038_s41598_024_61238_5 crossref_primary_10_1111_bju_12306 crossref_primary_10_1118_1_4906129 crossref_primary_10_1186_s12885_022_09432_4 crossref_primary_10_1016_j_juro_2015_02_015 crossref_primary_10_1109_TMI_2021_3139999 crossref_primary_10_1016_j_urology_2016_11_017 crossref_primary_10_1155_2014_819360 crossref_primary_10_1016_j_juro_2015_11_055 crossref_primary_10_1111_bju_12023 crossref_primary_10_1109_TBCAS_2017_2782815 crossref_primary_10_1016_j_urology_2017_10_051 crossref_primary_10_1002_cnm_2726 crossref_primary_10_3390_cancers14010001 crossref_primary_10_1007_s00330_014_3159_0 crossref_primary_10_1097_MOU_0b013e32835f899f crossref_primary_10_1016_j_eururo_2016_08_023 crossref_primary_10_1007_s00345_020_03487_3 crossref_primary_10_1364_AO_58_00A112 crossref_primary_10_1016_j_ejrad_2018_11_006 crossref_primary_10_1177_2051415816654596 crossref_primary_10_1007_s00261_018_1782_y crossref_primary_10_1002_jmri_27793 crossref_primary_10_1007_s11136_019_02205_w crossref_primary_10_1136_bmjopen_2020_041427 crossref_primary_10_1080_17843286_2019_1653511 crossref_primary_10_1007_s00261_016_0750_7 crossref_primary_10_1002_jmri_25641 crossref_primary_10_1148_radiol_2017162827 crossref_primary_10_1177_15330338211019418 crossref_primary_10_1016_j_juro_2014_02_005 crossref_primary_10_1016_j_juro_2017_04_017 crossref_primary_10_1109_TBME_2016_2582734 crossref_primary_10_3348_kjr_2015_16_1_90 crossref_primary_10_1038_s41598_018_21523_6 crossref_primary_10_1155_2014_439171 crossref_primary_10_1007_s11548_024_03258_0 crossref_primary_10_1016_j_juro_2013_05_052 crossref_primary_10_1097_MD_0000000000016122 crossref_primary_10_1111_bju_13082 crossref_primary_10_1002_cncr_30548 crossref_primary_10_1186_s13244_023_01556_w crossref_primary_10_1016_j_eururo_2016_01_032 crossref_primary_10_1016_j_juro_2014_02_080 crossref_primary_10_3348_kjr_2018_19_4_733 crossref_primary_10_1007_s00330_017_4939_0 crossref_primary_10_1016_j_brachy_2014_01_011 crossref_primary_10_3390_diagnostics10070441 crossref_primary_10_1097_MOU_0000000000000164 crossref_primary_10_48095_cccu2018033 crossref_primary_10_1016_j_euo_2018_07_005 crossref_primary_10_1002_pros_24844 crossref_primary_10_1007_s13193_016_0612_3 crossref_primary_10_1016_j_juro_2014_03_117 crossref_primary_10_1016_j_media_2014_02_009 crossref_primary_10_1259_bjr_20151056 crossref_primary_10_1016_j_juro_2015_12_083 crossref_primary_10_1109_TUFFC_2024_3465214 crossref_primary_10_1007_s11934_013_0387_9 crossref_primary_10_1016_j_urolonc_2020_03_019 crossref_primary_10_1016_j_eururo_2014_10_026 crossref_primary_10_1016_j_juro_2015_01_072 crossref_primary_10_12998_wjcc_v9_i36_11183 crossref_primary_10_1118_1_4885959 crossref_primary_10_1007_s00345_016_1970_8 crossref_primary_10_1007_s11547_014_0490_0 crossref_primary_10_1016_j_euo_2025_01_005 crossref_primary_10_1016_j_clinimag_2018_09_012 crossref_primary_10_1016_j_juro_2012_10_039 crossref_primary_10_1093_bjr_tqad036 crossref_primary_10_3390_jimaging8050133 crossref_primary_10_1111_1754_9485_12230 crossref_primary_10_1111_bju_13427 crossref_primary_10_1016_j_juro_2016_09_070 crossref_primary_10_1186_s12894_017_0241_3 crossref_primary_10_1016_j_urology_2015_10_023 crossref_primary_10_1111_bju_12335 crossref_primary_10_1111_bju_13023 crossref_primary_10_1016_j_juro_2015_05_078 crossref_primary_10_1097_COC_0000000000000308 crossref_primary_10_1111_bju_12690 crossref_primary_10_1016_j_urology_2016_08_022 crossref_primary_10_1089_end_2015_0864 crossref_primary_10_1016_j_juro_2013_04_118 crossref_primary_10_1007_s00345_016_1967_3 crossref_primary_10_1016_j_prro_2015_04_006 crossref_primary_10_1007_s00117_013_2608_0 crossref_primary_10_1016_j_media_2022_102620 crossref_primary_10_1016_j_urology_2019_02_037 crossref_primary_10_1016_j_urolonc_2016_03_005 crossref_primary_10_1016_j_juro_2014_04_094 crossref_primary_10_1016_j_juro_2017_10_069 crossref_primary_10_1146_annurev_med_053117_123215 crossref_primary_10_1097_MOU_0000000000000461 crossref_primary_10_1155_2024_2741986 crossref_primary_10_1016_j_urolonc_2016_03_001 |
| ContentType | Journal Article |
| Copyright | Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.juro.2012.08.095 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3792 |
| ExternalDocumentID | 23158413 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCRR NIH HHS grantid: UL1 RR024160 – fundername: NCI NIH HHS grantid: R01CA158627 – fundername: NCI NIH HHS grantid: R01 CA158627 |
| GroupedDBID | --- --K .55 .GJ .XZ 08P 0R~ 123 1B1 1CY 354 3O- 4.4 457 4G. 4Q1 4Q2 4Q3 53G 5RE 5VS 7-5 AAAAV AAEDT AAEDW AAGIX AAHPQ AAIQE AAJCS AAKAS AALRI AAMOA AAQFI AAQKA AAQQT AAQXK AASCR AASXQ AAXUO ABASU ABCQX ABDIG ABJNI ABLJU ABMAC ABOCM ABPPZ ABPXF ABVCZ ABWVN ABXYN ABZZY ACGFS ACILI ACLDA ACOAL ACRPL ACVFH ACXJB ACZKN ADCNI ADGGA ADGHP ADHPY ADMUD ADNKB ADNMO ADZCM AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFNMH AFTRI AFUWQ AGHFR AGQPQ AHOMT AHQNM AHQVU AHRYX AHVBC AI. AIGII AINUH AITUG AIZYK AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AMRAJ AOQMC ASGHL ASPBG AVWKF AZFZN BCGUY BELOY BYPQX C45 C5W CGR CS3 CUY CVF DIWNM DU5 EBS ECM EEVPB EIF EJD ERAAH EX3 F5P FCALG FDB FEDTE FGOYB GBLVA GNXGY GQDEL HLJTE HVGLF HZ~ H~9 IH2 IHE IKREB IKYAY IPNFZ J5H KMI L7B M41 MJL MO0 N4W NPM NQ- NTWIH O9- OAG OAH OB3 OBH ODMTH OGROG OHH OL1 OVD OWU OWV OWW OWY OWZ P2P QTD R2- RIG RLZ ROL RPZ SEL SES SJN SSZ TEORI TSPGW UDS UNMZH UV1 VH1 VVN WOW X7M XH2 XYM YFH YOC ZCG ZFV ZGI ZXP ZY1 ZZMQN 7X8 |
| ID | FETCH-LOGICAL-c584t-976199fe3d1efbfa65cec64d088faddd62d7fbe09fd885fcd694e3ea44e841df2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 235 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000312604800029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-3792 |
| IngestDate | Thu Oct 02 10:22:11 EDT 2025 Mon Jul 21 06:05:33 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c584t-976199fe3d1efbfa65cec64d088faddd62d7fbe09fd885fcd694e3ea44e841df2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/3561472 |
| PMID | 23158413 |
| PQID | 1239059130 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1239059130 pubmed_primary_23158413 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-Jan 20130101 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – month: 01 year: 2013 text: 2013-Jan |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of urology |
| PublicationTitleAlternate | J Urol |
| PublicationYear | 2013 |
| References | 16630688 - Eur Urol. 2006 Oct;50(4):738-48; discussion 748-9 21788047 - J Urol. 2011 Sep;186(3):850-4 21924545 - Eur Urol. 2012 Jan;61(1):177-84 20006859 - J Urol. 2010 Feb;183(2):520-7 18384857 - Urology. 2008 Oct;72(4):882-6 21502392 - Radiology. 2011 May;259(2):453-61 21177390 - Radiology. 2011 Feb;258(2):488-95 17085122 - J Urol. 2006 Dec;176(6 Pt 1):2432-7 19175099 - Med Phys. 2008 Dec;35(12):5397-410 18805628 - Eur Urol. 2009 Jan;55(1):1-8 21334018 - J Urol. 2011 Apr;185(4):1246-54 21555104 - Urol Oncol. 2011 May-Jun;29(3):334-42 11992052 - J Urol. 2002 Jun;167(6):2435-9 20124165 - J Clin Oncol. 2010 Mar 1;28(7):1117-23 21849184 - J Urol. 2011 Oct;186(4):1281-5 21825257 - J Clin Oncol. 2011 Sep 20;29(27):3669-76 19917860 - J Clin Oncol. 2010 Jan 1;28(1):126-31 21115873 - J Clin Oncol. 2011 Jan 10;29(2):228-34 11586201 - J Urol. 2001 Nov;166(5):1679-83 16507832 - J Natl Cancer Inst. 2006 Mar 1;98(5):355-7 17644125 - J Urol. 2007 Sep;178(3 Pt 2):S14-9 23158414 - J Urol. 2013 Jan;189(1):92 21464416 - J Clin Oncol. 2011 Jun 1;29(16):2185-90 22014798 - J Urol. 2011 Dec;186(6):2214-20 19786982 - Prostate Cancer Prostatic Dis. 2010 Mar;13(1):71-7 20080294 - Urology. 2010 May;75(5):1034-9 22322308 - Eur Radiol. 2012 Apr;22(4):746-57 23158415 - J Urol. 2013 Jan;189(1):91-2 21239006 - J Urol. 2011 Mar;185(3):815-20 18433013 - Cancer. 2008 Jun 15;112(12):2664-70 21944089 - J Urol. 2011 Nov;186(5):1818-24 17138129 - Urol Oncol. 2006 Nov-Dec;24(6):492-5 |
| References_xml | – reference: 21239006 - J Urol. 2011 Mar;185(3):815-20 – reference: 21924545 - Eur Urol. 2012 Jan;61(1):177-84 – reference: 11992052 - J Urol. 2002 Jun;167(6):2435-9 – reference: 18384857 - Urology. 2008 Oct;72(4):882-6 – reference: 19786982 - Prostate Cancer Prostatic Dis. 2010 Mar;13(1):71-7 – reference: 20124165 - J Clin Oncol. 2010 Mar 1;28(7):1117-23 – reference: 16507832 - J Natl Cancer Inst. 2006 Mar 1;98(5):355-7 – reference: 23158414 - J Urol. 2013 Jan;189(1):92 – reference: 21177390 - Radiology. 2011 Feb;258(2):488-95 – reference: 18805628 - Eur Urol. 2009 Jan;55(1):1-8 – reference: 21825257 - J Clin Oncol. 2011 Sep 20;29(27):3669-76 – reference: 21944089 - J Urol. 2011 Nov;186(5):1818-24 – reference: 20006859 - J Urol. 2010 Feb;183(2):520-7 – reference: 21115873 - J Clin Oncol. 2011 Jan 10;29(2):228-34 – reference: 20080294 - Urology. 2010 May;75(5):1034-9 – reference: 21849184 - J Urol. 2011 Oct;186(4):1281-5 – reference: 17138129 - Urol Oncol. 2006 Nov-Dec;24(6):492-5 – reference: 19917860 - J Clin Oncol. 2010 Jan 1;28(1):126-31 – reference: 21502392 - Radiology. 2011 May;259(2):453-61 – reference: 22322308 - Eur Radiol. 2012 Apr;22(4):746-57 – reference: 16630688 - Eur Urol. 2006 Oct;50(4):738-48; discussion 748-9 – reference: 17644125 - J Urol. 2007 Sep;178(3 Pt 2):S14-9 – reference: 21788047 - J Urol. 2011 Sep;186(3):850-4 – reference: 23158415 - J Urol. 2013 Jan;189(1):91-2 – reference: 17085122 - J Urol. 2006 Dec;176(6 Pt 1):2432-7 – reference: 19175099 - Med Phys. 2008 Dec;35(12):5397-410 – reference: 21555104 - Urol Oncol. 2011 May-Jun;29(3):334-42 – reference: 18433013 - Cancer. 2008 Jun 15;112(12):2664-70 – reference: 22014798 - J Urol. 2011 Dec;186(6):2214-20 – reference: 21334018 - J Urol. 2011 Apr;185(4):1246-54 – reference: 11586201 - J Urol. 2001 Nov;166(5):1679-83 – reference: 21464416 - J Clin Oncol. 2011 Jun 1;29(16):2185-90 |
| SSID | ssj0014572 |
| Score | 2.5369492 |
| Snippet | Targeted biopsy of lesions identified on magnetic resonance imaging may enhance the detection of clinically relevant prostate cancers. We evaluated prostate... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 86 |
| SubjectTerms | Aged Biopsy, Needle - methods Humans Magnetic Resonance Imaging - instrumentation Male Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology Ultrasonography, Interventional - instrumentation |
| Title | Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23158413 https://www.proquest.com/docview/1239059130 |
| Volume | 189 |
| WOSCitedRecordID | wos000312604800029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA7qiHhxX8aNCF6r0zZdchIRBw_OMIcR5lbSvmQY0bZ2Efz3vtd2mJMgeOmltITk5cv3tnyM3eAJK4KBNJZRIraEj-5ODEpYARD5R28MoLnE9SUYj8PZTE66gFvZlVUuMbEBasgSipHfIcJKpAIIuff5p0WqUZRd7SQ01lnPRSpDVh3MVlkE4TXiTaTcihtJOl3TTFvf9VYX1PxHscDwdiC93ylmc9QMd_87yD2205FM_tBaxT5b0-kB2xp1afRDVk-b-m8NPF5kefnNFylHIshBV01lVsozw3PqB0EmyhMyjIJThfycK3pnEF04nX_AP9Q8pT5Ijm57Rpd3aF6_V4UqSa6Jm5qCcfhfwqMj9jp8mj4-W53-gpUgLaksSSEOabQLtjaxUb6X6MQXgMBkEBbBdyAwscaVhjD0TAK-FNrVSggdChuMc8w20izVp4w7IUgFRijfuCKxkYW4rh0Lhf6aUVI7fXa9nNAI7ZuSFirVWV1Gqynts5N2VaK8vYgjQm6KA7Xdsz98fc62nUbJgqInF6xncHfrS7aZfFWLsrhqDAef48noB3rB0CY |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+biopsy+in+the+detection+of+prostate+cancer+using+an+office+based+magnetic+resonance+ultrasound+fusion+device&rft.jtitle=The+Journal+of+urology&rft.au=Sonn%2C+Geoffrey+A&rft.au=Natarajan%2C+Shyam&rft.au=Margolis%2C+Daniel+J+A&rft.au=MacAiran%2C+Malu&rft.date=2013-01-01&rft.issn=1527-3792&rft.eissn=1527-3792&rft.volume=189&rft.issue=1&rft.spage=86&rft_id=info:doi/10.1016%2Fj.juro.2012.08.095&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-3792&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-3792&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-3792&client=summon |